Compare BXC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXC | TECX |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | 1700 | 60 |
| Industry | Wholesale Distributors | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.2M | 545.3M |
| IPO Year | 2004 | N/A |
| Metric | BXC | TECX |
|---|---|---|
| Price | $56.09 | $30.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $86.00 | $75.25 |
| AVG Volume (30 Days) | 93.6K | ★ 167.5K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $2,801.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.78 | $14.39 |
| 52 Week High | $88.30 | $35.99 |
| Indicator | BXC | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 53.42 |
| Support Level | $52.71 | $17.71 |
| Resistance Level | $66.64 | $32.27 |
| Average True Range (ATR) | 2.44 | 1.57 |
| MACD | 1.21 | -0.32 |
| Stochastic Oscillator | 87.21 | 52.58 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.